Intrexon Corp Company Profile (NYSE:XON)

About Intrexon Corp (NYSE:XON)

Intrexon Corp logoIntrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company's domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company's synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company's technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NYSE:XON
  • CUSIP: N/A
  • Web:
  • Market Cap: $2.74 billion
  • Outstanding Shares: 119,606,000
Average Prices:
  • 50 Day Moving Avg: $21.10
  • 200 Day Moving Avg: $23.80
  • 52 Week Range: $18.41 - $32.90
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -41.69
  • P/E Growth: 0.60
Sales & Book Value:
  • Annual Revenue: $201.24 million
  • Price / Sales: 13.63
  • Book Value: $4.42 per share
  • Price / Book: 5.19
  • EBIDTA: ($89,610,000.00)
  • Net Margins: -93.97%
  • Return on Equity: -18.46%
  • Return on Assets: -12.13%
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 3.15%
  • Quick Ratio: 2.93%
  • Average Volume: 1.18 million shs.
  • Beta: 1.5
  • Short Ratio: 14.35

Frequently Asked Questions for Intrexon Corp (NYSE:XON)

What is Intrexon Corp's stock symbol?

Intrexon Corp trades on the New York Stock Exchange (NYSE) under the ticker symbol "XON."

How were Intrexon Corp's earnings last quarter?

Intrexon Corp (NYSE:XON) issued its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by $0.04. The business had revenue of $53.70 million for the quarter, compared to the consensus estimate of $49.08 million. Intrexon Corp had a negative net margin of 93.97% and a negative return on equity of 18.46%. The firm's revenue was up 23.7% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.55) earnings per share. View Intrexon Corp's Earnings History.

Where is Intrexon Corp's stock going? Where will Intrexon Corp's stock price be in 2017?

6 brokerages have issued 12-month target prices for Intrexon Corp's shares. Their predictions range from $35.00 to $57.00. On average, they expect Intrexon Corp's stock price to reach $45.80 in the next year. View Analyst Ratings for Intrexon Corp.

Who are some of Intrexon Corp's key competitors?

Who owns Intrexon Corp stock?

Intrexon Corp's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Third Security LLC (52.47%), FMR LLC (5.04%), Vanguard Group Inc. (3.61%), Iridian Asset Management LLC CT (3.25%), State Street Corp (2.28%) and Morgan Stanley (1.81%). Company insiders that own Intrexon Corp stock include Fred Hassan, Joel D Liffman, Nir Nimrodi, Randal J Kirk and Suma Krishnan. View Institutional Ownership Trends for Intrexon Corp.

Who sold Intrexon Corp stock? Who is selling Intrexon Corp stock?

Intrexon Corp's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, UBS Group AG, JPMorgan Chase & Co., Oracle Investment Management Inc., Frontier Capital Management Co. LLC, Morgan Stanley, Emerald Mutual Fund Advisers Trust and Bank of America Corp DE. View Insider Buying and Selling for Intrexon Corp.

Who bought Intrexon Corp stock? Who is buying Intrexon Corp stock?

Intrexon Corp's stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Vanguard Group Inc., Capital Advisors Inc. OK, First Trust Advisors LP, Credit Suisse AG, Third Security LLC, Peregrine Capital Management LLC and Iridian Asset Management LLC CT. Company insiders that have bought Intrexon Corp stock in the last two years include Fred Hassan, Joel D Liffman, Nir Nimrodi and Randal J Kirk. View Insider Buying and Selling for Intrexon Corp.

How do I buy Intrexon Corp stock?

Shares of Intrexon Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Intrexon Corp stock cost?

One share of Intrexon Corp stock can currently be purchased for approximately $22.93.

Analyst Ratings

Consensus Ratings for Intrexon Corp (NYSE:XON) (?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $45.80 (99.74% upside)

Analysts' Ratings History for Intrexon Corp (NYSE:XON)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/4/2017Stifel NicolausReiterated RatingBuy$57.00HighView Rating Details
3/14/2017WunderlichLower Price TargetBuy$50.00 -> $35.00HighView Rating Details
2/3/2017JMP SecuritiesSet Price TargetBuy$42.00N/AView Rating Details
12/29/2016Northland SecuritiesInitiated CoverageOutperform$40.00N/AView Rating Details
11/11/2016JPMorgan Chase & Co.Reiterated RatingHoldN/AView Rating Details
8/16/2016Griffin SecuritiesReiterated RatingBuy$55.00N/AView Rating Details
3/3/2016Bank of America CorpReiterated RatingNeutral$41.00 -> $38.00N/AView Rating Details
3/1/2016MizuhoReiterated RatingNeutral$28.00 -> $29.00N/AView Rating Details
8/11/2015Merriman CapitalUpgradeNeutral -> Buy$85.00N/AView Rating Details
(Data available from 5/24/2015 forward)


Earnings History for Intrexon Corp (NYSE:XON)
Earnings by Quarter for Intrexon Corp (NYSE:XON)
Earnings History by Quarter for Intrexon Corp (NYSE:XON)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.22)($0.26)$49.08 million$53.70 millionViewN/AView Earnings Details
3/1/2017Q416($0.23)($0.37)$52.53 million$46.00 millionViewListenView Earnings Details
11/9/2016Q316($0.21)($0.24)$51.70 million$48.99 millionViewListenView Earnings Details
8/9/2016Q216($0.26)($0.42)$53.78 million$52.50 millionViewN/AView Earnings Details
5/10/2016Q1($0.20)($0.55)$46.26 million$43.40 millionViewListenView Earnings Details
2/29/2016Q415($0.18)($0.28)$41.82 million$41.50 millionViewListenView Earnings Details
11/9/2015Q3($0.21)($0.34)$40.84 million$53.40 millionViewN/AView Earnings Details
8/10/2015Q215($0.04)$0.01$55.93 million$44.90 millionViewListenView Earnings Details
5/11/2015Q115($0.12)$0.25$32.90 million$33.80 millionViewListenView Earnings Details
3/2/2015Q414($0.16)$0.18$26.11 million$31.10 millionViewN/AView Earnings Details
11/13/2014Q314($0.16)($0.53)$19.40 million$21.20 millionViewN/AView Earnings Details
8/14/2014Q214($0.13)($0.11)$9.39 million$11.80 millionViewN/AView Earnings Details
5/7/2014Q1$0.06$0.04$11.25 million$7.90 millionViewN/AView Earnings Details
3/31/2014Q413($0.14)($0.13)$8.38 million$7.10 millionViewN/AView Earnings Details
11/7/2013($0.03)$0.15$9.79 million$6.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Intrexon Corp (NYSE:XON)
2017 EPS Consensus Estimate: ($0.79)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.22)($0.22)($0.22)
Q2 20171($0.19)($0.19)($0.19)
Q3 20171($0.20)($0.20)($0.20)
Q4 20171($0.18)($0.18)($0.18)
(Data provided by Zacks Investment Research)


Dividend History for Intrexon Corp (NYSE:XON)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Intrexon Corp (NYSE:XON)
Insider Ownership Percentage: 55.10%
Institutional Ownership Percentage: 84.51%
Insider Trades by Quarter for Intrexon Corp (NYSE:XON)
Institutional Ownership by Quarter for Intrexon Corp (NYSE:XON)
Insider Trades by Quarter for Intrexon Corp (NYSE:XON)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/13/2016Randal J KirkCEOBuy34,606$28.90$1,000,113.40View SEC Filing  
12/12/2016Joel D LiffmanSVPBuy8,500$28.62$243,270.00View SEC Filing  
12/1/2016Fred HassanDirectorBuy6,900$29.02$200,238.00View SEC Filing  
8/29/2016Nir NimrodiSVPBuy4,000$26.12$104,480.00View SEC Filing  
5/13/2016Randal J KirkCEOBuy41,830$23.92$1,000,573.60View SEC Filing  
12/11/2015Randal J KirkCEOBuy124,475$29.85$3,715,578.75View SEC Filing  
12/7/2015Randal J KirkCEOBuy237,525$30.69$7,289,642.25View SEC Filing  
12/4/2015Suma KrishnanSVPSell20,900$35.66$745,294.00View SEC Filing  
1/27/2015Randal J KirkCEOBuy555,556$27.00$15,000,012.00View SEC Filing  
5/13/2014Donald LehrInsiderBuy1,850$15.99$29,581.50View SEC Filing  
5/13/2014Randal KirkCEOBuy65,173$15.19$989,977.87View SEC Filing  
5/9/2014Kelly HuangSVPBuy3,200$15.78$50,496.00View SEC Filing  
5/9/2014Krish KrishnanCOOBuy20,900$14.21$296,989.00View SEC Filing  
3/27/2014Randal KirkCEOBuy243,001$25.72$6,249,985.72View SEC Filing  
3/4/2014Gregory Ian FrostSVPBuy100,000$25.95$2,595,000.00View SEC Filing  
8/13/2013Jeffrey B KindlerDirectorBuy33,000$16.00$528,000.00View SEC Filing  
8/13/2013Randal J KirkCEOBuy1,887,500$16.00$30,200,000.00View SEC Filing  
8/13/2013Thomas D ReedInsiderBuy1,800$16.00$28,800.00View SEC Filing  
8/13/2013Thomas R KasserSVPBuy5,000$16.00$80,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Intrexon Corp (NYSE:XON)
Latest Headlines for Intrexon Corp (NYSE:XON)
DateHeadline logoIntrexon to Present at Upcoming Investor and Industry Conferences - May 24 at 8:04 AM logoIntrexon (XON) Presents At Bank of America Merrill Lynch 2017 Health Care Conference - Slideshow - May 22 at 7:46 PM logoWhat You Missed in Intrexon's Quarterly Report - May 19 at 1:53 PM logoIntrexon Appoints Dr. Mark Carnegie-Brown as CEO of Oxitec - May 19 at 1:53 PM logoZIOPHARM Oncology Announces Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma to be Presented at the 2017 ASCO Annual Meeting - May 17 at 11:22 PM logoFibrocell to Present at Inaugural Cell & Gene Exchange 2017 - May 17 at 8:08 AM logoIntrexon to Present at the Bank of America Merrill Lynch 2017 ... - PR Newswire (press release) - May 16 at 8:05 AM logoIntrexon Breaks Above 200-Day Moving Average - Bullish for XON - May 15 at 7:52 PM logoIntrexon Corp (XON) Forecasted to Post FY2019 Earnings of $0.31 Per Share - May 15 at 10:02 AM logoIntrexon to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference - May 15 at 8:20 AM logoToday's Research Reports on Stocks to Watch: Himax Technologies and Intrexon Corporation - May 12 at 8:20 PM logoIntrexon Corp (XON) Receives Consensus Recommendation of "Buy" from Analysts - May 12 at 4:28 PM logoHow these two Tampa Bay companies got the financing to grow their technology - May 12 at 3:18 PM logoWhy Intrexon Is Soaring Today - Motley Fool - May 11 at 8:21 PM logoEdited Transcript of XON earnings conference call or presentation 10-May-17 8:30pm GMT - May 11 at 8:21 PM logoEarnings Reaction History: Intrexon Corporation, 28.6% Follow ... - Nasdaq - May 11 at 3:21 PM logoIntrexon Corp (XON) Issues Earnings Results - May 11 at 2:46 PM logo10-Q: INTREXON CORP - May 11 at 3:46 AM logoIntrexon Corp 2017 Q1 - Results - Earnings Call Slides - May 11 at 3:46 AM logoIntrexon Announces First Quarter 2017 Financial Results - May 11 at 3:46 AM logoIntrexon reports 1Q loss - May 11 at 3:46 AM logo4 Biotech and Specialty Pharma Stocks With 80% to 200% Upside Potential - May 10 at 9:38 AM logoIntrexon and Darling to expand insect-based feed production - May 10 at 9:38 AM logoIntrexon and Darling to Build Commercial-scale Production of Insect-Based Advanced Feed Ingredients - May 10 at 9:38 AM logoFibrocell and Intrexon Announce Two Oral Presentations at the 20th Annual Meeting of the American Society of Gene ... - GlobeNewswire (press release) - May 9 at 8:16 PM logoBRIEF-Huvepharma EOOD and Intrexon enter into research agreement - May 9 at 8:41 AM logoHuvepharma to Utilize Intrexon's Proprietary Fungal Expression Platform to Produce Key Animal Feed Enzyme - May 9 at 8:41 AM logoIntrexon Corp. breached its 50 day moving average in a Bearish Manner : XON-US : May 8, 2017 - May 8 at 8:57 PM logoGilead Sciences Is A Value Trap - Cramer's Lightning Round (5/5/17) - May 8 at 8:12 AM logoFibrocell Announces Data Safety Monitoring Board Recommends Continuation of Phase 1/2 Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa - May 8 at 8:12 AM logo-$0.23 Earnings Per Share Expected for Intrexon Corp (XON) This Quarter - May 5 at 7:52 AM logoZiopharm Oncology: Key To The CAR-T Mint - May 3 at 7:04 PM logoIntrexon to Announce First Quarter 2017 Financial Results on May 10th - May 3 at 9:35 AM logoWill Intrexon (XON) Pull Off a Surprise in Q1 Earnings? - May 2 at 6:52 PM logoIntrexon Corp (XON) Upgraded to "Buy" at Zacks Investment Research - May 2 at 2:26 PM logoIntrexon Corp (XON) Earning Somewhat Positive News Coverage, Study Shows - May 2 at 9:54 AM logoZIOPHARM Oncology Reports First Quarter 2017 Financial Results and Provides Update on Recent Activities - May 1 at 7:49 PM logoIntrexon Appoints Vinita Gupta, Leading Pharma Executive, to its Board of ... - April 28 at 2:41 AM logoIntrexon Corp. – Value Analysis (NYSE:XON) : April 27, 2017 - April 28 at 2:41 AM logoIntrexon Appoints Vinita Gupta, Leading Pharma Executive, to its Board of Directors - April 27 at 11:32 AM logoIntrexon Corp. breached its 50 day moving average in a Bullish Manner : XON-US : April 26, 2017 - April 26 at 5:22 PM logoIntrexon Corp (XON) Receiving Favorable Media Coverage, Study Finds - April 26 at 8:13 AM logoCommit To Purchase Intrexon Corp At $13, Earn 11.9% Using ... - Nasdaq - April 25 at 7:39 PM logoIntrexon subsidiary could begin releasing 'mutant' mosquitoes in U.S by this summer - April 24 at 7:06 PM logoAct Now - Shareholder Alert: Monteverde & Associates PC Announces An Investigation Of GenVec, Inc. - GNVC - April 23 at 10:31 PM logoSomewhat Favorable Press Coverage Extremely Likely to Impact Intrexon Corp (XON) Share Price - April 23 at 11:48 AM logoZIOPHARM Oncology to Present Updated Clinical Results of Gene Therapy Candidate Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma at the 2017 ASCO Annual Meeting - April 21 at 1:23 AM logoSomewhat Positive News Coverage Somewhat Likely to Impact Intrexon Corp (XON) Stock Price - April 20 at 9:23 AM logoIntrexon Corp (XON) Receives Consensus Rating of "Buy" from Brokerages - April 17 at 6:59 PM logo$48.79 Million in Sales Expected for Intrexon Corp (XON) This Quarter - April 16 at 9:16 AM



Intrexon Corp (XON) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by Staff